Segall Bryant & Hamill’s Protagonist Therapeutics PTGX Stock Holding History

Segall Bryant & Hamill’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.3M	Buy	214,724 +2,010	+0.9%	+$210K	0.31%	94
2026 Q1	$22.4M	Buy	212,714 +83,654	+65%	+$7.41M	0.32%	96
2025 Q4	$11.3M	Buy	129,060 +5,935	+5%	+$486K	0.15%	214
2025 Q3	$8.18M	Buy	123,125 +2,966	+2%	+$169K	0.11%	257
2025 Q2	$6.64M	Buy	+120,159	New	+$5.77M	0.09%	283
2024 Q4	–	Sell	-120,301	Closed	-$5.41M	–	628
2024 Q3	$5.41M	Buy	120,301 +1,739	+1%	+$70.3K	0.07%	317
2024 Q2	$4.11M	Buy	+118,562	New	+$3.47M	0.07%	321

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Segall Bryant & Hamill's PTGX Position: Q2 2026 in Review

Segall Bryant & Hamill increased its Protagonist Therapeutics (PTGX) stake by 0.94% in Q2 2026, buying an estimated $210K and bringing the position to 214,724 shares worth $26.3M. The position accounts for 0.31% of the portfolio, ranked #94.

Segall Bryant & Hamill first reported a position in PTGX in Q2 2024 and has held it in 7 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Segall Bryant & Hamill held 214,724 shares of Protagonist Therapeutics worth $26.3M as of Q2 2026.
Segall Bryant & Hamill bought 2,010 Protagonist Therapeutics shares in Q2 2026, an estimated $210K.
Protagonist Therapeutics made up 0.31% of Segall Bryant & Hamill's portfolio in Q2 2026, its #94 holding.
Segall Bryant & Hamill first reported a position in Protagonist Therapeutics in Q2 2024 and has held it in 7 quarters since.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.